F
Federica De Galitiis
Researcher at University of L'Aquila
Publications - 34
Citations - 1025
Federica De Galitiis is an academic researcher from University of L'Aquila. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 11, co-authored 24 publications receiving 546 citations.
Papers
More filters
Journal ArticleDOI
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Alessio Cortellini,Melissa Bersanelli,Sebastiano Buti,Katia Cannita,Daniele Santini,Fabiana Perrone,Raffaele Giusti,Marcello Tiseo,Maria Michiara,Pietro Di Marino,Nicola Tinari,Michele De Tursi,Federica Zoratto,Enzo Veltri,Riccardo Marconcini,Francesco Malorgio,Marco Russano,Cecilia Anesi,Tea Zeppola,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Gian Carlo Antonini Cappellini,Federica De Galitiis,Maria Giuseppa Vitale,Francesca Rastelli,Federica Pergolesi,Rossana Berardi,Silvia Rinaldi,Marianna Tudini,Rosa Rita Silva,Annagrazia Pireddu,Francesco Atzori,Rita Chiari,Biagio Ricciuti,Andrea De Giglio,Daniela Iacono,Alain Gelibter,Mario Occhipinti,Alessandro Parisi,Giampiero Porzio,Maria Concetta Fargnoli,Paolo A. Ascierto,Corrado Ficorella,Clara Natoli +44 more
TL;DR: Overweight could be considered a tumorigenic immune-dysfunction that could be effectively reversed by ICIs and BMI could be a useful predictive tool in clinical practice and a stratification factor in prospective clinical trials with ICIs.
Journal ArticleDOI
Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma
Michele Del Vecchio,Lorenza Di Guardo,Paolo A. Ascierto,Antonio M. Grimaldi,Vanna Chiarion Sileni,Jacopo Pigozzo,Virginia Ferraresi,Carmen Nuzzo,Gaetana Rinaldi,Alessandro Testori,Pier Francesco Ferrucci,Paolo Marchetti,Federica De Galitiis,Paola Queirolo,Elena Tornari,Riccardo Marconcini,Luana Calabrò,Michele Maio +17 more
TL;DR: Ipilimumab may be a feasible treatment option in pretreated patients with metastatic mucosal melanoma, and warrants further investigation in prospective clinical trials.
Journal ArticleDOI
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study
Alessio Cortellini,Sebastiano Buti,Daniele Santini,Fabiana Perrone,Raffaele Giusti,Marcello Tiseo,Melissa Bersanelli,Maria Michiara,Antonino Grassadonia,Davide Brocco,Nicola Tinari,Michele De Tursi,Federica Zoratto,Enzo Veltri,Riccardo Marconcini,Francesco Malorgio,Carlo Garufi,Marco Russano,Cecilia Anesi,Tea Zeppola,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Gian Carlo Antonini Cappellini,Federica De Galitiis,Maria Giuseppa Vitale,Roberto Sabbatini,Sergio Bracarda,Rossana Berardi,Silvia Rinaldi,Marianna Tudini,Rosa Rita Silva,Annagrazia Pireddu,Francesco Atzori,Rita Chiari,Biagio Ricciuti,Daniela Iacono,Maria Rita Migliorino,Antonio Rossi,Giampiero Porzio,Katia Cannita,Valeria Ciciarelli,Maria Concetta Fargnoli,Paolo A. Ascierto,Corrado Ficorella +44 more
TL;DR: The finding of a greater incidence of irAEs among female patients ranks among the "hot topics" in gender-related differences in immuno-oncology.
Journal ArticleDOI
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Jason J. Luke,Piotr Rutkowski,Paola Queirolo,M. Del Vecchio,Jacek Mackiewicz,Vanna Chiarion-Sileni,Luis Merino,Muhammad A. Khattak,Dirk Schadendorf,Georgina V. Long,Paolo A. Ascierto,Mario Mandalà,Federica De Galitiis,Andrew Haydon,Reinhard Dummer,Jean-Jacques Grob,Caroline Robert,G. Carlino,Peter Mohr,Andrew Poklepovic,Vernon K. Sondak,Richard A. Scolyer,John M. Kirkwood,Ke Chen,Scott J. Diede,Sama Ahsan,Nageatte Ibrahim,Alexander M.M. Eggermont +27 more
TL;DR: Pembrolizumab prolongs progression-free and overall survival among patients with advanced melanoma and recurrence-free survival in resected stage III disease and as adjuvant therapy in patients with completely resecting, high-risk, stage II melanoma is assessed.
Journal ArticleDOI
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
Alessio Cortellini,Melissa Bersanelli,Daniele Santini,Sebastiano Buti,Marcello Tiseo,Katia Cannita,Fabiana Perrone,Raffaele Giusti,Michele De Tursi,Federica Zoratto,Riccardo Marconcini,Marco Russano,Tea Zeppola,Cecilia Anesi,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Alain Gelibter,Federica De Galitiis,Maria Giuseppa Vitale,Francesca Rastelli,Marianna Tudini,Rosa Rita Silva,Francesco Atzori,Rita Chiari,Biagio Ricciuti,Andrea De Giglio,Maria Rita Migliorino,Domenico Mallardo,Vito Vanella,Claudia Mosillo,Sergio Bracarda,Silvia Rinaldi,Rossana Berardi,Clara Natoli,Corrado Ficorella,Giampiero Porzio,Paolo A. Ascierto +37 more
TL;DR: Considering the previously evidenced association between higher BMI and better outcome, the current finding about the relationship between BMI and irAEs occurrence can contribute to consideration of these findings as the upside of the downside, which underlies an 'immunogenic phenotype'.